Epidemiology of Treatment Resistant Depression in Taiwan

Overview

The purpose of this study is to assess the epidemiology of Treatment Resistant Depression (TRD) in the nationally insured population in Taiwan including incidence, duration of clinical episodes, and prevalence by age and sex.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: February 2016

Detailed Description

This is a retrospective study of approximately one million subjects randomly selected from an anonymized database National Health Insurance Research Database (NHIRD). Participants aged 18 years or older who have had neither a depression diagnosis nor a dispensing of an antidepressant medication in the last four months of 2004 will enter the study when they receive in 2005 a depression diagnosis and a dispensing of an antidepressant medication within 30 days of each other and will be followed up to 8 years or until they have 4 months with neither a depression diagnosis nor a dispensing of an antidepressant medication. Treatment Resistant Depression (TRD) Incidence, TRD prevalence by age and sex and duration of clinical episodes will be estimated.

Arms, Groups and Cohorts

  • Taiwan Participants with Treatment Resistant Depression
    • Taiwan participants with Depression will be followed up to 8 years for incidence and duration of treatment resistant depression.

Clinical Trial Outcome Measures

Primary Measures

  • Incidence Percentage of Participants with Treatment Resistant Depression
    • Time Frame: Approximately 8 Years
    • The percentage of beneficiaries of Taiwan’s health insurance plan who developed treatment resistant depression during 2005
  • Prevalence Percentage of Participants with Treatment Resistant Depression
    • Time Frame: Approximately 8 Years
  • Duration of an episode of Depression
    • Time Frame: Approximately 8 Years
    • Time from onset of depression to cessation of depression visits and medications.

Secondary Measures

  • Healthcare costs
    • Time Frame: Approximately 8 Years
    • Direct healthcare cost associated with depression treatment will be assessed.
  • Number of Participants With Comorbidities
    • Time Frame: Approximately 8 Years
  • Medications used by Participants with Treatment Resistant Depression
    • Time Frame: Approximately 8 Years

Participating in This Clinical Trial

Inclusion Criteria

  • Participants who have been continuously enrolled in the insurance plan since January 1, 2004 (ignoring breaks of less than 30 days) and have not received an exclusion diagnosis and during the last 4 months of 2004, a) Have not received a diagnosis of depression and b) Have not received a dispensing of an AD medication
  • Participants with a diagnosis of a depressive disorder including dysthymic disorder (International Classification of Diseases [ICD]-9 codes 296 depression-related, 300.4, 311) and Major Depressive Disorder (ICD-9 296.2, 296.3) will be followed through December 31, 2013

Exclusion Criteria

  • Participants who receive following diagnosis will be excluded, a) Mania, b) Schizophrenia (ICD-9 codes 295), c) Bipolar disorder (ICD-9 codes 296 bipolar-related), D) Dementia (ICD-9 codes 290 or 294); Note: Major depressive disorder (MDD) with psychotic behavior (ICD 296.24 for single episode, ICD 296.34 for recurrent episode) is not an exclusion

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Johnson & Johnson Pte Ltd
  • Collaborator
    • Elysia Group
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Johnson & Johnson Pte Ltd Clinical Trial, Study Director, Johnson & Johnson Pte Ltd

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.